| BMI | Body mass index |
| CV | Cardiovascular |
| cAMP | Cyclic-adenosine-monophosphate |
| CVOT | Cardiovascular outcome trial |
| DPP-4 | Dipeptidyl peptidase 4 |
| FDA | United States Food and Drug Administration |
| FFA | Free fatty acids |
| GIP | Glucose-dependent insulinotropic polypeptide |
| GIPRs | GIP receptors |
| GLP-1 | Glucagon-like peptide-1 |
| GLP-1 R | Glucagon-like peptide-1 receptor |
| GLP-1 RA | Glucagon-like peptide-1 receptor agonists |
| GR | Glucagon receptor |
| HbA1c | Glycated hemoglobin A1c |
| i.v. | Intravenous |
| MACE | Major cardiovascular events |
| MI | Myocardial infarction |
| OGTT | Oral glucose tolerance test |
| PEG | Polyethylene glycol |
| SGLT | Sodium-glucose co-transporter type |
| SD | Standard deviation |
| T2DM | Type 2 diabetes mellitus |